Abacavir
- TRADE NAMES: Epzicom (ViiV); Triumeq (ViiV); Trizivir (ViiV); Ziagen (ViiV)
- INDICATIONS: HIV infections in combination with other antiretrovirals
- CLASS: Nucleoside analog reverse transcriptase inhibitor
- HALF-LIFE: 1.5 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Alcohol, Arbutamine, Argatroban, Arsenic, Darunavir, Ganciclovir, Lopinavir, Methadone, Phenobarbital, Phenytoin, Protease inhibitors, Ribavirin, Rifampin, Tipranavir, Valganciclovir
PREGNANCY CATEGORY: C
Check for presence of HLA B*57:01
Epzicom is abacavir and lamivudine; Triumeq is abacavir, dolutegravir and lamivudine; Trizivir is abacavir, lamivudine and zidovudine.
HYPERSENSITIVITY REACTIONS, LACTIC ACIDOSIS and SEVERE HEPATOMEGALY, and EXACERBATIONS OF HEPATITIS B
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN.
HAIR.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
RENAL.
RESPIRATORY.
OTHER.
Page last updated 11/04/2021
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
